[The correction of hyperuricemia in patients with different forms of nephrolithiasis using allopurinol and Allomaron].
Metabolic status was assessed in 48 patients with nephrolithiasis followed-up for 4 years. Allopurinol and allomaron-treated patients were examined biochemically by 17 parameters of the blood and urine. The effects of the drugs were compared. It is concluded that in hyperuricemia up to 0.37 +/- 0.02 mmol/l allomaron is more effective (1--2 pills a day). In higher hyperuricemia allopurinol is preferable (4 pills a day). Allomaron can be also used (1--2 pills a day) under the control of urinalysis.
Darenkov
A F
AF
Konstantinova
O V
OV
Ianenko
E K
EK
D000328:Adult; D000368:Aged; D000493:Allopurinol / Q000627:therapeutic use*; D001553:Benzbromarone / Q000627:therapeutic use*; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007669:Kidney Calculi / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D013607:Tablets; D014527:Uric Acid / Q000097:blood*
D004338:Drug Combinations; D013607:Tablets; C086509:allopurinol, benzbromarone drug combination; D014527:Uric Acid; D001553:Benzbromarone; D000493:Allopurinol
Korrektsiia giperurikemii u bol'nykh s razlichnymi formami nefrolitiaza allopurinolom i allomaronom.